YBL-006 is a monoclonal antibody discovered from our proprietary library that targets programmed cell death protein 1 (PD-1) and is currently undergoing Phase 1 clinical trials as a PD-1 immune checkpoint inhibitor. The binding of PD-L1 and PD-L2 proteins on the surface of cancer cells to PD-1 proteins on the surface of T cells causes T cells to become unable to properly recognize the cancer cells and, therefore, not attack them. YBL-006 is being developed independently by Y-Biologics, binding to PD-1 and inhibiting an immune escape mechanism of cancer cells.

LAG-3, a protein expressed on activated T cells or regulatory T cells (Tregs) (CD4+ or CD8+), inhibits T cell activation by binding MHC class II molecules or LSECtin on antigen presenting cells (APCs) or cancer cells, thereby enabling immune escape by cancer cells. YBL-011 targets LAG-3 on the surface of T cells, preventing binding to MHC class II molecules on APCs or cancer cells, simultaneously enhancing T cell activity and suppressing Treg cell activity to induce cancer cell death.

YBL-003 is an immune checkpoint inhibitor being developed as a therapeutic antibody candidate for the treatment of solid tumors. It regulates the function of macrophages and activity of T cells to reactivate the immune system in the tumor microenvironment and kill cancer cells. Furthermore, the scope of the indications for YBL-003 can be expanded to include gastric cancer, lung cancer, breast cancer, and more, illustrating its high potential for use as an immuno-oncology agent targeting solid tumors.

AR087 is an immuno-oncology agent that activates immune cells and kills cancer cells by binding to a target antigen expressed on cancer cells. Y-Biologics plans to develop AR087 as a therapeutic agent for various solid tumors through a joint research collaboration with HK inno.N.